National Health (Originator Brand) Amendment Determination 2018 (No. 2) (PB 26 of 2018) (Cth)

PB 26 of 2018

National Health (Originator Brand) Amendment Determination 2018 (No. 2)

National Health Act 1953

I, LISA LA RANCE, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under subsection 99ADB (6B) of the National Health Act 1953.

Dated      26   March 2018

______________________________________

LISA LA RANCE

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

1. Name of Determination

(1)     This Determination is the National Health (Originator Brand) Amendment Determination 2018 (No. 2).

(2)     This Determination may also be cited as PB 26 of 2018.

1. Commencement

This Determination commences on 1 April 2018.

1. Amendments to PB 100 of 2015

Schedule 1 amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015).

Schedule 1     Amendments

(section 3)

[1]   Schedule 1 (after table item 28)

insert:

28A Budesonide with eformoterol Symbicort Rapihaler 50/3 Symbicort Rapihaler 100/3 Symbicort Rapihaler 200/6 Symbicort Turbohaler 100/6 Symbicort Turbohaler 200/6 Symbicort Turbohaler 400/12

[2]   Schedule 1 (table item 41)

repeal the items, substitute:

41	Cephalexin	Keflex
41A	Certolizumab pegol	Cimzia
41 B	Chorionic gonadotrophin	Pregnyl

[3]   Schedule 1 (after table item 68)

insert:

68A Ganciclovir Cymevene